Clinical Trial Update: GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating GM1 as a preventive treatment to reduce nab-paclitaxel–associated chemotherapy-induced peripheral neuropathy in breast cancer pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Peripheral Neuropathy

Drugs mentioned

• GM1 (monosialotetrahexosyl ganglioside)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Chemotherapy-induced Peripheral Neuropathy (CIPN) | Phase 3 | Status: RECRUITING